



HHS Public Access

Author manuscript

Lancet. Author manuscript; available in PMC 2017 September 06.

Published in final edited form as:

Lancet. 2014 April 12; 383(9925): 1279. doi:10.1016/S0140-6736(14)60608-5.

Expression of concern: the SCIPIO trial

The Lancet Editors

The Lancet, London NW1 7BY, UK

On March 25, 2014, Gretchen Brodnicki, Harvard Medical School's Dean for Faculty and Research Integrity, wrote to *The Lancet* to inform us that “Harvard Medical School (HMS) and Brigham and Women's Hospital (BWH) are reviewing concerns about the integrity of certain data generated in a laboratory at BWH and included in the following published paper...[the] *2011 Lancet SCIPIO paper*”.¹ The focus of this investigation is on two supplemental figures published online (figures 2A and 3). As far as we are aware, the investigation is confined to the work completed at BWH. Gretchen Brodnicki continues, “Because review of this paper is ongoing, we cannot provide additional details at this time.” In further discussions with Harvard Medical School, we have been told that the current investigation into this aspect of the work reported in the SCIPIO trial is likely to take several months. As soon as *The Lancet* receives further information, we will inform readers accordingly.

References

1. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. *Lancet*. 2011; 378:1847–57. [PubMed: 22088800]